BHWM
NBIX icon

Bay Harbor Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Bay Harbor Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22K Buy
31
+20
+182% +$2.97K ﹤0.01% 415
2026
Q1 		$1.45K Buy
11
+2
+22% +$265 ﹤0.01% 640
2025
Q4 		$1.28K Buy
9
+4
+80% +$579 ﹤0.01% 571
2025
Q3 		$701 Buy
5
+1
+25% +$135 ﹤0.01% 611
2025
Q2 		$502 Buy
4
+2
+100% +$229 ﹤0.01% 644
2025
Q1 		$221 Buy
+2
New +$253 ﹤0.01% 635

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bay Harbor Wealth Management's NBIX Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 182% in Q2 2026, buying an estimated $2.97K and bringing the position to 31 shares worth $5.22K. The position accounts for ﹤0.01% of the portfolio, ranked #415.

Bay Harbor Wealth Management first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bay Harbor Wealth Management held 31 shares of Neurocrine Biosciences worth $5.22K as of Q2 2026.
  • Bay Harbor Wealth Management bought 20 Neurocrine Biosciences shares in Q2 2026, an estimated $2.97K.
  • Neurocrine Biosciences made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #415 holding.
  • Bay Harbor Wealth Management first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.